Anti-RARS Rabbit Monoclonal Antibody for WB, IF-P, IHC-P, ELISA - P54136

Core Product Specifications and Parameters

Biological Background: RARS Function and Localization

• Arginine--tRNA ligase, cytoplasmic (alternative names: Arginyl-tRNA synthetase, ArgRS), is encoded by the RARS1 gene (also known as RARS) and belongs to the class-I aminoacyl-tRNA synthetase family. It catalyzes the ATP-dependent attachment of arginine to its cognate tRNA, an essential step in protein translation on cytoplasmic ribosomes (PubMed:25288775).
  Related references:
  PMID:25288775
• Forms part of a macromolecular complex with other tRNA synthetases and accessory proteins, facilitating efficient channeling of aminoacyl-tRNAs to the ribosome. This multi-synthetase complex enhances the fidelity and speed of protein synthesis.
• Involved in the regulated secretion and processing of the AIMP1/p43 precursor. It modulates the cleavage and release of the inflammatory cytokine EMAP2 (endothelial monocyte-activating polypeptide 2) from AIMP1, linking translation to innate immunity (PubMed:17443684).
  Related references:
  PMID:17443684
• Localizes predominantly to the cytosol and is enriched in the cytoplasmic compartment, consistent with its role in translation and multi-synthetase complex assembly. No nuclear or organelle-specific isoforms are reported.
• Post-translationally modified by acetylation, and the gene is subject to alternative initiation, producing isoforms with distinct N-termini. These modifications may regulate enzyme activity, stability, or complex formation.
• Mutations in RARS1 are associated with leukodystrophy, a group of disorders affecting brain white matter, underscoring the importance of this gene in neural development and function. Its moonlighting roles beyond translation highlight its versatility.
• Keywords include aminoacyl-tRNA synthetase, ATP-binding, ligase, protein biosynthesis, acetylation, and disease variant, reflecting its core catalytic function and disease relevance.

Experimental Guidance and Technical Tips

• The immunogen is a recombinant protein spanning residues 1–300 of human RARS. This N-terminal region may contain linear and conformational epitopes recognized by the monoclonal antibody in various assays. For WB, consider reducing and non-reducing conditions to assess epitope accessibility.
• Since the target is cytoplasmic, IF-P and IHC-P protocols should include a permeabilization step (e.g., 0.1–0.5% Triton X-100) for optimal detection. Validate antibody specificity using control cells or tissues with known RARS expression levels.
• The antibody cross-reacts with mouse RARS, enabling its use in mouse model systems. However, sequence homology should be confirmed across the immunogen region; a BLAST alignment may inform expected reactivity in other species.
• For ELISA applications, test the antibody pair with recombinant antigen or native cell lysates. Titrate the coating and detection antibody concentrations to achieve a linear dynamic range suitable for your analytical requirements.
• As a rabbit monoclonal, it typically offers high affinity and lot-to-lot consistency. Still, each new lot should be qualified in your assay of interest, and working dilutions must be determined empirically for your specific sample type and protocol.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio serves as an integrated sourcing partner for IVD raw materials, empowering diagnostic manufacturers, laboratories, and research institutes with one-stop access to validated antibodies, antigens, and ancillary reagents. In the field of aminoacyl-tRNA synthetase and translational research, our portfolio includes RARS antibodies, supporting your protein synthesis and inflammation studies. Contact us for bulk orders, customized reagent sourcing, and technical consultation—we bridge your concept to clinic with rigorous quality and supply chain expertise.